Genzyme in Belgium
Our sales & marketing offices in Diegem
Genzyme established its first offices in Belgium in 1993 to support the European expansion of its diagnostics and therapeutics sales activities. In 2000, with the acquisition of BioMatrix, Genzyme Belgium expanded to include a team of sales and marketing professionals for Belgium and Luxembourg. Genzyme Belgium comprises all business activities for the Belux region as well as some European functions. After the acquisition by Sanofi in 2011 the offices moved to the Sanofi premises in Diegem, just outside the Brussels region,
Our manufacturing facilities in Geel
In October 2001, Genzyme Corporation acquired the Belgian part of Pharming N.V. in Geel, Belgium to develop Genzyme's first biotherapeutics manufacturing facility in Europe.
The manufacturing facility comprises a continuous production line for the manufacturing of enzymes for enzyme replacement therapies and a fed-batch production line for the manufacturing of therapeutic monoclonal antibodies.
Currently the enzyme for treatment of Pompe disease, a rare genetic, often fatal, disease of the muscle, is manufactured. Regulatory approval for commercial production of this enzyme was received in 2009-2010 for the EU, Japan, Canada, US and Brazil.
In 2010, the construction of an additional, autonomous plant has started to support long-term growth and new future products.
Genzyme's overall investment in Geel totals around 600 million and the site currently employs 550 people.
Genzyme Belgium Sales & Marketing
Airport Plaza - Montreal Building
Leonardo Da Vinci laan 19
Tel: +32 2 710 5400
Fax: +32 2 710 5409